维普中文期刊产品整合服务
41篇 您的检索式:作者名="PERLETTI G"
    题名 作者 年代 出处 被引量
1Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction显示文摘我们以前在范畴 II 长期的细菌的前列腺炎(CBP ) 表明了 fluoroquinolone-macrolide 联合治疗的安全和功效。这研究的目的是回顾地基于 azithromycin 的联合为 CBP 比较 microbiological 和二个处理计划的临床的调查结果(500   mg,三次每周) 与一次每日的 500-mg 或 ciprofloxacin 的 750-mg 剂量(Cipro-500 或 Cipro-750 队,分别地) 。azithromycin 的联合管理(1500  有以 750   的率的 ciprofloxacin 的 mg 星期 −1) ;为 4 个星期而非在 500   的 mg 天 −1 ;为 6 个星期的 mg 天 −1 从 62.35 % 增加了根除率;到 77.32 %并且从 71.76 % 的全部的细菌学的成功;到 85.57 %。在煽动性的白血球计数和浆液的疼痛和 voiding 症状 / 症状和重要减小地的重要减少前列腺特定的抗原(PSA ) 在两个组在整个 18 月的后续经期被支撑。射精的疼痛, haemospermia 和早泄显著地在两个组在 microbiological 根除上被稀释,但是后者在 Cipro-750 队更即时减退了。总共, 59 个 Cipro-750 病人显示出 mild-to-severe 在基线的可勃起的机能障碍(编辑) ,当 22 个病人没在 microbiological 根除上并且在整个后续时期有编辑时。在结论 fluoroquinolone-macrolide,治疗在病原体根除和 CBP 症状变细导致了,包括疼痛, voiding 骚乱和性机能障碍。为 4 个星期的 ciprofloxacin 的一次每日的 750-mg 剂量与 500-mg 剂量相比显示出提高的根除率和更低的煽动性的白血房间计数 6 个星期。我们的结果是开的推进未来的确认。Vittorio Magri Emanuele Montanari Visnja Skerk Alemka Markotic Emanuela Marras Antonella Restelli Kurt G Naber Gianpaolo Perletti 2011Asian Journal of Andrology2011,13,6:12
2Critical issues in chronic prostatitis显示文摘Magri V Perletti G Bartoletti R 2010Arch Ital Urol Androl2010,82,2:1
3Critical issues in chronicprostatitis显示文摘Magri V Perletti G Bartoletti R 2010Arch Ital Urol Andro12010,82,2:1
4Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors显示文摘Perletti G Concari P Gistfini R 0,,:1
5Antitumor activity of Endostatin against carcinogen-induced rat primary mammary tumors显示文摘Perletti G Concari p Giardini R 2000Cancer Res2000,60,7:1
6Antitumorac- tivity of endostatin against carci nagen induced ratprimary mammary tumors显示文摘PERLETTI G CONCARI P GIARDINI R 2000Cancer Res2000,60,7:1
7Generation of VSV-G pseudotyped lentiviral particles in 293T cells显示文摘Perletti G Osti D Marras E 2004J Cell Mol Med2004,8,1:1
8CXA-101:cephalosporin antibiotic显示文摘Perletti G Magri V Wagenlehner F M 2010Drugs Fui2010,35,12:1
9Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors 显示文摘Perletti G Concari P Giardini R 2000Cancer Res2000,60,7:1
10Antitumor Activity of Endostatin against Carcinogen-induced Rat Primary Mammary Tumors显示文摘Perletti G Concari P Giardini R 2000Cancer Res2000,60,7:1
11Antitumor activity of endostatinagainst carcinogen-induced rat primary mammary tumors显示文摘Perletti G Concari P Giardini R 2000CancerRes2000,60,7:1
12Comparative analysis of immune responses and cytokine ptofiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV显示文摘Radaelli A Zanotto C Perletti G 2003Vaccine2003,21,:1
13Chronic prostati-tis and erectile dysfunction: results from a cross-sectional study显示文摘Magri V Perletti G Montanari E 2008Arch Ital Urol Androl2008,80,4:1
14Antitumor activity of endostatin against carcinogen induced rat primary mammary tumors显示文摘Perletti G Concari P Giardini R 2000Cancer Res2000,60,7:1
15Antitumor activity of endostatin against carcinogen-induced rat primary mammary tmnors显示文摘Perletti G Concari P Giardini R 2000Cancer Res2000,60,7:1
16Distinctive cellular roles for novel protein kinase C isocnzymes 显示文摘Perletti G Terrian DM 2006Curr Pharm Des2006,12,24:1
17Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors显示文摘PERLETTI G CONCARI P GIARDINI R 2000Cancer Res2000,60,7:1
18Prevention and modulation of aminoglycoside ototoxicity显示文摘Perletti G Vral A Patrosso M.C Marras E Cerlan I Wil-lems P Fasano M Magri V 0,,:1
19Critical issues in chronic prostatitis显示文摘Magri V Perletti G Bartoletti R 2010Arch Ital Urol Androl2010,82,2:1
20Antitumor activity of endostatin against carcinogen - induced rat primary ma, ary tumors 显示文摘Perletti G Concari P Giardini R 2005Cancer Res2005,60,:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费